MAA房产信托(MAA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

MAA MAA房产信托

交易中 04-19 14:48:47 EDT

125.51

+0.89

+0.71%

最高126.37	最低125.24	成交量25.11万
今开125.68	昨收124.62	日振幅0.91%
总市值146.50亿	流通市值145.15亿	总股本1.17亿
成交额3,159万	换手率0.22%	流通股本1.16亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"MAA","market":"US","secType":"STK","nameCN":"MAA房产信托","latestPrice":125.51,"timestamp":1713552522997,"preClose":124.62,"halted":0,"volume":251110,"delay":0,"floatShares":115649692,"shares":116727107,"eps":4.707599,"marketStatus":"交易中","marketStatusCode":2,"change":0.89,"latestTime":"04-19 14:48:47 EDT","open":125.68,"high":126.3699,"low":125.235,"amount":31591970.8119,"amplitude":0.009107,"askPrice":125.56,"askSize":27,"bidPrice":125.49,"bidSize":13,"shortable":3,"etf":0,"ttmEps":4.707599,"exchange":"NYSE","tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1713556800000},"adr":0,"adjPreClose":124.62,"adrRate":0,"dividendRate":0.044618,"preHourTrading":{"tag":"盘前","latestPrice":124.62,"preClose":124.62,"latestTime":"08:02 EDT","volume":1,"amount":124.62,"timestamp":1713528172826},"postHourTrading":{"tag":"盘后","latestPrice":124.62,"preClose":124.62,"latestTime":"18:17 EDT","volume":64748,"amount":8068887.82,"timestamp":1713478665420},"volumeRatio":0.388482},"requestUrl":"/m/hq/s/MAA/","defaultTab":"news","newsList":[{"id":"2425269640","title":"我国首个肾癌免疫疗法获批，君实生物拓益®为中国患者带来新选择","url":"https://stock-news.laohu8.com/highlight/detail?id=2425269640","media":"美通社","top":-1,"share":"https://www.laohu8.com/m/news/2425269640?lang=zh_cn&edition=full","pubTime":"2024-04-07 15:49","pubTimestamp":1712476140,"startTime":"0","endTime":"0","summary":"据统计，2022年中国肾癌新发病例和死亡病例分别约为7.7万例和4.6万例2。此次特瑞普利单抗新适应症的获批开启了中国晚期肾癌靶免联合的新篇章，将会彻底改写我国晚期肾癌的临床实践，更重要的是能够为中高危患者带来新的治疗选择！特瑞普利单抗联合阿昔替尼疗法的获批填补了中国人群肾癌一线免疫治疗的空白，相较靶向药单药治疗，特瑞普利单抗靶免联合疗法能够显著提升患者的PFS，将为我国广大晚期肾癌患者带来福音。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4381480_ZH81480_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2422133959","title":"基石药业公布2023年年度业绩及公司近期业务进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2422133959","media":"美通社","top":-1,"share":"https://www.laohu8.com/m/news/2422133959?lang=zh_cn&edition=full","pubTime":"2024-03-27 22:00","pubTimestamp":1711548000,"startTime":"0","endTime":"0","summary":"2023年总收入为人民币4.638亿元，其中商业化收入人民币3.681亿元。稳健的财务状况，截至2023年12月31日现金储备为10.3亿人民币；年内亏损减少57%。预期两项申请将在2024年陆续获批。苏州2024年3月27日 /美通社/ -- 基石药业，一家专注于研究开发及商业化创新肿瘤免疫疗法及精准治疗药物的领先生物制药公司，今日公布其2023年年度业绩及近期业务亮点。业务摘要 截至2023年12月31日止年度及截至本公告日期，我们的产品管线及业务经营均已取得重大进展。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4372459_ZH72459_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2406292912","title":"复宏汉霖完成H药 斯鲁利单抗首批海外发货","url":"https://stock-news.laohu8.com/highlight/detail?id=2406292912","media":"美通社","top":-1,"share":"https://www.laohu8.com/m/news/2406292912?lang=zh_cn&edition=full","pubTime":"2024-01-25 20:24","pubTimestamp":1706185440,"startTime":"0","endTime":"0","summary":"免疫检查点抑制剂的出现为SCLC领域的治疗带来新希望，H药为复宏汉霖自主研发的重组人源化抗PD-1单抗注射液，也是全球首个且目前唯一获批一线治疗小细胞肺癌的抗PD-1单抗。此次H药发货印度尼西亚将为当地患者带来新希望并提高其长期生存的机会。截至目前，H药已有4项适应症获批上市，2项适应症上市申请分别在中国和欧盟获受理，10余项临床试验同步在全球开展。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4320937_ZH20937_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2380568222","title":"单季度销售额3.3亿美金，新一代“重磅炸弹”的诞生","url":"https://stock-news.laohu8.com/highlight/detail?id=2380568222","media":"氨基观察","top":-1,"share":"https://www.laohu8.com/m/news/2380568222?lang=zh_cn&edition=full","pubTime":"2023-11-01 11:56","pubTimestamp":1698811006,"startTime":"0","endTime":"0","summary":"创新药领域新王与旧王的权力更迭，一直在重复上演。修美乐、伊布替尼等药王日薄西山之际，一些新晋种子选手，正在不断浮出水面。最近的例子，是Argenx的艾加莫德。最新的财报显示，艾加莫德第三季度销售额达到了3.29亿美元，前9个月的销售额为8.16亿美元。从这一趋势来看，艾加莫德在上市销售的第二个完整年度，将迈入重磅...","market":"hk","thumbnail":"https://inews.gtimg.com/om_ls/OJJPqjYAjtWgD85yYk_r0XbcsVEYAwDCQ04cdGRsrGXVoAA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/OJJPqjYAjtWgD85yYk_r0XbcsVEYAwDCQ04cdGRsrGXVoAA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20231101A03U7A00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20231101A03U7A00","is_publish_highlight":false,"gpt_icon":0},{"id":"2378287527","title":"复宏汉霖与Intas深化合作，携手护航H药扬帆欧洲、印度市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2378287527","media":"美通社","top":-1,"share":"https://www.laohu8.com/m/news/2378287527?lang=zh_cn&edition=full","pubTime":"2023-10-27 19:06","pubTimestamp":1698404760,"startTime":"0","endTime":"0","summary":"复宏汉霖已于2018年6月与Intas子公司Accord展开合作，授予其汉曲优在欧洲、部分中东及北非地区、部分独联体国家的独家商业化权利，并于2021年进一步授予Intas汉曲优在美国及加拿大地区的独家开发与商业化权利。通过与Intas进一步深化合作，我们希望加速推动H药在全球范围内实现更广泛的可及性，为改善当地患者的治疗效果和生存质量贡献力量。\" 复宏汉霖高级副总裁兼首席商务发展官曹平女士表示：\"复宏汉霖和Intas子公司Accord于2018年达成合作。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4251014_ZH51014_1","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.maac.com","stockEarnings":[{"period":"1week","weight":-0.0558},{"period":"1month","weight":-0.0443},{"period":"3month","weight":-0.0785},{"period":"6month","weight":-0.0312},{"period":"1year","weight":-0.1724},{"period":"ytd","weight":-0.0732}],"compareEarnings":[{"period":"1week","weight":-0.0357},{"period":"1month","weight":-0.0314},{"period":"3month","weight":0.0354},{"period":"6month","weight":0.186},{"period":"1year","weight":0.2062},{"period":"ytd","weight":0.0509}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Mid-America Apartment Communities, Inc.是田纳西州的一家公司。该公司是一家专注于多户家庭、自我管理的房地产投资信托基金（REIT）。该公司拥有、运营、收购和有选择地开发主要位于美国东南部、西南部和中大西洋地区的公寓社区。公司的首要经营目标是保护和增长现有物业价值，保持稳定且不断增加的现金流，通过房地产投资周期的各个部分为股息和分配提供资金，并通过有纪律的增长创造股东价值。","yearOnYearQuotes":[{"month":1,"riseRate":0.633333,"avgChangeRate":-0.000504},{"month":2,"riseRate":0.451613,"avgChangeRate":-0.002597},{"month":3,"riseRate":0.612903,"avgChangeRate":0.017626},{"month":4,"riseRate":0.612903,"avgChangeRate":0.01302},{"month":5,"riseRate":0.633333,"avgChangeRate":0.014267},{"month":6,"riseRate":0.633333,"avgChangeRate":0.013387},{"month":7,"riseRate":0.533333,"avgChangeRate":0.0152},{"month":8,"riseRate":0.433333,"avgChangeRate":-0.006026},{"month":9,"riseRate":0.5,"avgChangeRate":-0.005293},{"month":10,"riseRate":0.566667,"avgChangeRate":-0.007062},{"month":11,"riseRate":0.6,"avgChangeRate":0.006373},{"month":12,"riseRate":0.7,"avgChangeRate":0.020519}],"exchange":"NYSE","name":"MAA房产信托","nameEN":"Mid-America Apartment Communities"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"MAA房产信托(MAA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供MAA房产信托(MAA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"MAA房产信托,MAA,MAA房产信托股票,MAA房产信托股票老虎,MAA房产信托股票老虎国际,MAA房产信托行情,MAA房产信托股票行情,MAA房产信托股价,MAA房产信托股市,MAA房产信托股票价格,MAA房产信托股票交易,MAA房产信托股票购买,MAA房产信托股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"MAA房产信托(MAA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供MAA房产信托(MAA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}